Fatma Nur Korkmaz, Asena Gökçay Canpolat, Klara Dalva, Atilla Halil Elhan, Mustafa Şahin, Demet Çorapçıoğlu, Özgür Demir
{"title":"Determination of the Relationship Between the Development and Recurrence of Subacute Thyroiditis and Human Leukocyte Antigen Subtypes.","authors":"Fatma Nur Korkmaz, Asena Gökçay Canpolat, Klara Dalva, Atilla Halil Elhan, Mustafa Şahin, Demet Çorapçıoğlu, Özgür Demir","doi":"10.1089/gtmb.2023.0386","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> There are several studies investigating the role of human leukocyte antigens (HLA) in the development and recurrence of subacute thyroiditis (SAT). The HLA subtypes associated with SAT were usually determined in a population-based manner and <i>HLA-B*35</i>, <i>HLA-B*18:01</i>, <i>HLA-C*04:01</i>, and <i>HLA-DRB1*01</i> were detected to play a role in the disease susceptibility and prognosis. The aim of this study was to determine HLA alleles associated with the tendency of recurrence and prevention of SAT within the Turkish population. <b><i>Methods:</i></b> This prospective study was conducted with 51 SAT patients and 720 healthy bone marrow donor volunteers. HLA-A, -B, -C, -DRB1, and -DQB1 were genotyped using next-generation sequencing. <b><i>Results:</i></b> The frequency of <i>HLA-A*02:09</i>, <i>HLA-B*35:01/35:02/35:03</i>, <i>HLA-C*04:01</i>, <i>HLA-DRB1*12:01</i>, <i>and DRB1*13:03</i> were associated with an increased risk of SAT development (Odds Ratio: 22.4, 9.5, 10.3, 4.2, and 3.5, respectively). While <i>HLA-A*02:09</i>, <i>HLA-B*35:01</i>, <i>HLA-B*44:02 HLA-C*07:18</i>, <i>and HLA-C*16:04</i> were associated with nonrelapsing SAT, <i>HLA-DR*12:01</i>was associated with relapsing SAT. <i>HLA-B*35:02</i>, <i>HLA-B*35:03</i>, and <i>HLA-C*04:01</i> were more frequent both in relapsing and nonrelapsing groups according to control group. The frequency of <i>HLA-B*18:01</i>, reported as a risk factor previously, was similar in the SAT and control groups (<i>p</i> = 0.959). <i>HLA-DRB1*11:01</i> was associated with a lower risk of SAT development. <b><i>Conclusions:</i></b> Along with -<i>B*358</i> and <i>-C*04</i>, <i>HLA-A*02:09</i> was detected as an important risk factor for SAT development in our population. <i>HLA-DRB1*11:01</i> appears to be the protective HLA subtype against SAT. <i>HLA-A*02:09</i>, <i>HLA-B*35:01</i>, <i>HLA-B*44:02</i>, <i>HLA-C*07:18</i>, <i>HLA-C*16:04</i>, <i>HLA-DQ*06:03</i>, and <i>HLA-DR*12:01</i> subtypes can establish a tendency to relapsing or nonrelapsing SAT.</p>","PeriodicalId":12603,"journal":{"name":"Genetic testing and molecular biomarkers","volume":"28 1","pages":"2-9"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genetic testing and molecular biomarkers","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1089/gtmb.2023.0386","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There are several studies investigating the role of human leukocyte antigens (HLA) in the development and recurrence of subacute thyroiditis (SAT). The HLA subtypes associated with SAT were usually determined in a population-based manner and HLA-B*35, HLA-B*18:01, HLA-C*04:01, and HLA-DRB1*01 were detected to play a role in the disease susceptibility and prognosis. The aim of this study was to determine HLA alleles associated with the tendency of recurrence and prevention of SAT within the Turkish population. Methods: This prospective study was conducted with 51 SAT patients and 720 healthy bone marrow donor volunteers. HLA-A, -B, -C, -DRB1, and -DQB1 were genotyped using next-generation sequencing. Results: The frequency of HLA-A*02:09, HLA-B*35:01/35:02/35:03, HLA-C*04:01, HLA-DRB1*12:01, and DRB1*13:03 were associated with an increased risk of SAT development (Odds Ratio: 22.4, 9.5, 10.3, 4.2, and 3.5, respectively). While HLA-A*02:09, HLA-B*35:01, HLA-B*44:02 HLA-C*07:18, and HLA-C*16:04 were associated with nonrelapsing SAT, HLA-DR*12:01was associated with relapsing SAT. HLA-B*35:02, HLA-B*35:03, and HLA-C*04:01 were more frequent both in relapsing and nonrelapsing groups according to control group. The frequency of HLA-B*18:01, reported as a risk factor previously, was similar in the SAT and control groups (p = 0.959). HLA-DRB1*11:01 was associated with a lower risk of SAT development. Conclusions: Along with -B*358 and -C*04, HLA-A*02:09 was detected as an important risk factor for SAT development in our population. HLA-DRB1*11:01 appears to be the protective HLA subtype against SAT. HLA-A*02:09, HLA-B*35:01, HLA-B*44:02, HLA-C*07:18, HLA-C*16:04, HLA-DQ*06:03, and HLA-DR*12:01 subtypes can establish a tendency to relapsing or nonrelapsing SAT.
期刊介绍:
Genetic Testing and Molecular Biomarkers is the leading peer-reviewed journal covering all aspects of human genetic testing including molecular biomarkers. The Journal provides a forum for the development of new technology; the application of testing to decision making in an increasingly varied set of clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. This is the definitive resource for researchers, clinicians, and scientists who develop, perform, and interpret genetic tests and their results.
Genetic Testing and Molecular Biomarkers coverage includes:
-Diagnosis across the life span-
Risk assessment-
Carrier detection in individuals, couples, and populations-
Novel methods and new instrumentation for genetic testing-
Results of molecular, biochemical, and cytogenetic testing-
Genetic counseling